in men by using oFSH as an immunogen. This is a prerequisite for obtaining significant reduction in the qual-
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There appears to be a clear consensus on the need for 5 To whom correspondence should be addressed follicle stimulating hormone (FSH) in maintaining quantitative spermatogenesis in the monkey (Sheela Rani et al., 1978;  A study of 140 days duration was performed to examine Murty et al., 1979; Wickings et al., 1980; Moudgal, 1981 ; Raj if human male volunteers (n ⍧ 5) respond to ovine follicle et al., 1982) , human (Matsumoto et al., 1986; Gromoll et al. , stimulating hormone (oFSH) immunization (administered 1996) and hamster (Lerchl et al., 1993) . However, there is adsorbed on Alugel on days 1, 20, 40 and 70) by producing evidence both for and against the need for FSH in regulating antibodies capable of both binding and neutralizing bioacspermatogenesis in the adult rat (Dym et al., 1979 ; Vaishnav tivity of human FSH. The kinetics of antibody production and Moudgal, , 1994 Shetty et al., 1996) and mice (Singh for both the immunogen (oFSH) and the cross- reactive et al., 1995) .
antigen (hFSH) were essentially similar. The volunteers
Earlier work from our laboratory has shown that adult male responded only to the first two immunizations. The boosters fertile bonnet monkeys immunized with ovine FSH (oFSH) given on days 40 and 70 were ineffective, probably because generate antibodies capable of binding monkey as well as of the presence of substantial amounts of circulating antihuman FSH (hFSH; Moudgal et al., 1992) . A consequence of body to oFSH. Of the antibodies generated to oFSH, 25-bioneutralization of endogenous FSH by the circulating anti-45% bound hFSH with a mean binding affinity of 0.65ϫ10 9 body is disruption in spermatogenesis, leading to oligospermia ⍨ 0.53 M -1 . The binding capacities at the time of high and infertility (Moudgal et al., 1992; Aravindan et al., 1993) .
(30-80 days of immunization) and low (>110 days) titres
Adopting such an approach for male contraception appeared were 346 ⍨ 185 and 10.5 ⍨ 5.8 ng hFSH/ml respectively. attractive, as it had no effect on serum testosterone and libido, During the period of high titre, free serum FSH (value in a problem that besets other steroid-based male contraceptive normal males 1-5 ng/ml) was not monitorable. A 50 µl procedures currently under test. Extensive pre-clinical toxicoaliquot of the antiserum obtained from different volunteers logy studies carried out in the rat (by N.Sethi, CDRI, Lucknow, between days 30 and 80 and on day 140 blocked binding India) and the monkey (by S.Sehgal, PGIMER, Chandigarh, of 125 I-labelled hFSH to its receptor by 82 ⍨ 9.7 and 53 India) have revealed that the oFSH vaccine at the doses tested ⍨ 12.2% respectively. The antibody produced was specific (1ϫ and 5ϫ proposed human dose) was not harmful and was for FSH, and no significant change in the values of related free from toxicity (Sehgal et al., 1991) . We report in this paper glycoprotein hormones (luteinizing hormone/testosterone the results of a pilot study on immunization of five human and thyroid stimulating hormone/thyroxine) were recorded.
male volunteers with the oFSH vaccine. The objectives of this Seminal plasma transferrin, a marker of Sertoli cell as study were twofold: to determine whether oFSH administered well as of seminiferous tubular function, showed marked adsorbed on Alugel (a relatively mild adjuvant cleared for reduction (30-90%) following immunization with oFSH.
human use) elicits an immune response in the human male Considering that endogenous FSH remained neutralized similar to that in the monkey, and whether oFSH immunization for approximately one sperm cycle only (65 days), the carried out thus is likely to be harmless and non-toxic to reduction in sperm counts (30-74%) exhibited by some the human. volunteers is encouraging. Immunization with oFSH did not result in any significant changes in haematology, serum Materials and methods biochemistry or hormonal profiles. There was no production of antibodies capable of interacting with non-specific
The vaccine

tissues. It is concluded that it should be possible to obtain
The oFSH used as the immunogen was isolated in the laboratory using conventional purification procedures (Moudgal et al., 1992 ) from a sustained long-term blockade of endogenous FSH action freeze-dried sheep pituitaries imported from Waitaki International tion) by methods described earlier (Moudgal et al., 1992) . To determine the extent of cross-reactivity of the oFSH antibody with Biosciences (Christ Church, New Zealand). Pituitaries from this source were preferred as sheep in New Zealand are certified free of hFSH, 1:100 diluted serum samples from individual human volunteers were incubated in the presence and absence of hFSH (1 µg/tube) schedule-1 diseases such as foot and mouth, rinderpest, vesicular stomatitis, anthrax, swine fever, lumpy skin disease, contagious bovine overnight at room temperature followed by addition of 125 I-labelled oFSH (150 000 cpm/tube) and a further incubation for 5-6 h. Next, pleuropneumonia and scrapie. The vaccine grade oFSH was also characterized for purity by electrophoretic procedures using approthe antigen-antibody complex in solution was precipitated by adding polyethylene glycol (PEG 6000); the pellet was monitored after priate radioimmuno-and radioreceptor assays. The purified preparation (batch no. 4) was tested for the presence of mycoplasma, as well centrifugation and washing for radioactivity. Percentage reactivity was calculated by assuming binding of 125 I-labelled oFSH to the as haemadsorbing and non-adsorbing viruses and other extraneous non-specific disease-causing agents by the Serum Institute (Poona, antibody in the absence of hFSH to be 100%. The bioneutralizing activity of the antisera was determined using a sheep testicular FSH India), a laboratory which routinely undertakes quality control tests using World Health Organization (WHO, 1988 ) guidelines on vaccines receptor binding inhibition assay as described earlier (Aravindan et al., 1993) . The presence, if any, of unreacted 'free FSH' in the produced for use in humans. The adjuvant used was Alugel (aluminium hydroxide gel; Superfos, Vedbaek, Denmark), and the vaccine formulasera of immunized volunteers was determined using a two-step radioreceptor assay system standardized in the laboratory. In this tion using pyrogen-free distilled water as well as the ampouling itself were performed using the GMP facility of Karnataka Antibiotics Ltd.
assay, the sera of volunteers (100 µl) were incubated with a fixed aliquot of a rat testicular receptor preparation (a 30 000 g pellet) for (Bangalore, India). Care was taken to prevent cross-contamination by ampouling each of the doses separately.
2 h at room temperature followed by centrifugation and washing. The resuspended receptor pellet was then incubated with 125 I-labelled Selection of volunteers hFSH for 1 h at room temperature, followed by washing and monitoring of receptor-bound radioactivity. A standard curve was The volunteers chosen were normal healthy men aged 34-41 years constructed by substituting volunteer sera with different aliquots of who had completed their families. Besides screening them for normal a hFSH solution of known concentration. The range of the assay was health, the sera of individual volunteers were tested prior to their from 0.3 to 25 ng hFSH/tube. inclusion in the study for the absence of autoantibodies to mitochonTo determine whether immunization with oFSH evoked production dria, smooth muscle, nuclear, thyroid microsomal, thyroglobulin, of antibodies to non-specific tissues, the reaction of sera with processed parietal cell, adrenal, pancreas and pituitary. They were also tested tissue obtained from fresh autopsied organs was assessed using for the absence of C-reactive protein, rheumatoid factor and human indirect immunofluorescence. Briefly, all sera were diluted 1:10 and immunovirus (HIV). Out of 14 volunteers screened, the five who allowed to react with different tissue substrates for 30 min at 37°C. passed all tests were recruited to the study.
After extensive washing, the sections were treated with an appropriate Approval for the study fluorescein-conjugated anti-human immunoglobulin G. The sections were mounted in buffered glycerol and viewed in a Zeiss fluorescent This study was approved by the Indian Council of Medical Research, microscope and the intensity of reaction was arbitrarily graded fromNew Delhi, the Drug Controller, Government of India and the Ethics to ϩ to ϩϩϩϩ. An enzyme-linked immunosorbent assay was used Committee for safe human experimentation of the Ramaiah Medical for HIV and the latex test to detect rheumatoid factor. College Hospital, Bangalore. Each of the volunteers provided signed Semen obtained periodically by masturbation was analysed for letters of informed consent. sperm counts, viability and gross motility of spermatozoa according to the WHO (1992) manual. The sperm-free seminal plasma was Vaccination protocol stored below 4°C until used for the measurement of transferrin Each of the volunteers received s.c. 1.0 ml of the gel suspension concentration by an appropriate radioimmunoassay. Human recombincontaining 1 mg of oFSH on day 1 and on day 20 a further 1 ml of ant transferrin and goat antiserum to transferrin were purchased from suspension containing 0.3 mg of oFSH. Booster doses of 0.1 mg of Cappel (Westchester, PA, USA). oFSH were administered on days 40 and 70 of immunization. Each of the above injections was preceded by a test dose of 0.1 ml given intradermally 30 min prior to the main dose. The dose schedule used here was primarily based on data obtained from earlier studies in Results monkeys (Moudgal et al., 1992) .
All the five volunteers maintained normal health over the entire period of 140 days (treatment for 70 days and post- sampling
a ANA ϭ antinuclear; SMA ϭ antismooth muscle; PCA ϭ parietal cell; AMA ϭ antimitochondrial; PIT ϭ antipituitary; ADR ϭ antiadrenal; PAN ϭ antipancrease; THYR ϭ antithyroid; CRP ϭ C-reactive protein; LAT ϭ latex test for rheumatoid factor.
20, 30, 40, 50 and 70) and post-treatment (on days 80, one sample showed faint smooth muscle antibodies, in another case faint antibodies to parietal cells were detected. During 100 and 140 days) phases for a variety of parameters. The haematological parameters analysed included haemoglobin, immunization, sera from three volunteers exhibited increased amounts of rheumatoid factor and C-reactive protein activity, total lymphocyte count, percentage of neutrophils, lymphocytes, eosinophils, packed cell volume and erythrocyte sedibut these disappeared in two of these volunteers by day 140. mentation rate (ESR). All of these parameters remained within Titration of antibodies to ovine and human FSH the normal range for the duration of the study. The serum biochemistry carried out included analysis for fasting blood
The relative antibody concentration as a function of time for both oFSH and hFSH showed a similar pattern, maximal sugar, urea, creatinine, triglyceride, high-density lipoprotein, very-low-density lipoprotein, low-density lipoprotein, serum activity being exhibited between days 30 and 80 of immunization. The antibody titre started to fall by day 110 and reached glutamicϪoxalacetic transaminase and serum glutamicϪ pyruvic transaminase. Values for all volunteers for the duration minimal values beyond day 140 of immunization ( Figure 1 ). Except for volunteer 1, who showed a slightly delayed response, of the study were within the normal range. The serum concentrations of LH, testosterone, TSH, triiodothyronine, thyroxine, the volunteers exhibited significant increments in oFSH antibody titres by day 30 and maximal values were maintained cortisol and prolactin analysed at different phases of immunization were also within the normal range for the entire study through day 80. The antibody titres to hFSH relative to the immunogen (oFSH) were substantially low. Since a proportion period (Table I) .
of the cross-reactive antibody produced would have been Immunopathological screening of sera of volunteers at differneutralized by endogenous circulating hFSH, the hFSH antient stages of oFSH immunization body titre determined represents only the excess 'free' antibody pool. It appears that all of the human volunteers responded Sera of individual volunteers obtained on days 1, 70 and 140 of immunization were analysed for the presence of only to the first two injections of oFSH, given on days 1 and 20, but not to the boosters of 100 µg oFSH given on days 40 autoantibodies to a variety of tissue-specific antigens (Table II) . None of the patients exhibited significant antibody titres to and 70. The cross-reactivity of the oFSH antibody with hFSH was measured by determining binding to 125 I-labelled oFSH thyroid microsomes or adrenal and pancreatic islet cells. While showed differences in their ability to inhibit binding of 125 Ilabelled hFSH to the receptor. This ability was maximal (82 Ϯ 9.7%) when the antibody titre was high, and when the titre fell to low values (by day 140) the % inhibition was also reduced (53 Ϯ 12.2%). When the antibody titre was relatively high, free FSH (not bound to the antibody) in the sera was undetectable by the two-step radioreceptor assay employed (Figure 2 ).
Semen characteristics and seminal plasma transferrin
The semen samples collected from individual volunteers during the pre-treatment, treatment and post-treatment phase were analysed for normality according to the WHO (1992) protocol. No marked changes were observed in the motility or viability (range 40-60%) of the ejaculated spermatozoa. No significant morphological abnormalities were noticeable. Sperm counts obtained on days -7 and 0 of immunization (considered as control) were compared to those obtained on days 50 and 70 (representing treatment phase) and days 100 and 140 (representing post-treatment phase) of immunization. Of the five volunteers, four showed reduction of~33%, while one volunteer (no. 9) showed a 64% reduction in sperm count (Table IV) . As the effect of immunization is generally extended into the early post-treatment phase, it is not surprising that some volunteers showed reduced sperm counts even between days 110 and 140.
Seminal plasma transferrin was measured using a human transferrin radioimmunoassay system. Using a recombinant human transferrin preparation as a standard, the assay was able to measure within the range 5-100 ng/tube. Individual volunteers showed marked reduction (in the range of 30-90%) in seminal plasma transferrin compared with normal values. The % reduction observed varied as a function of days of hFSH with great avidity. From the profile of the antibody titre to ovine and human FSH it can be inferred that the immunological response to epitopes in these two proteins is in the presence and absence of excess amount of hFSH, and this ranged between 26 and 45%.
essentially similar. This is not surprising, as considerable homology exists between the β subunits of ovine and human Characterization of antibodies cross-reactive with hFSH FSH (Ward and Bousfield, 1990) . All five volunteers responded to the immunogen, peak antibody titres being obtained in three The antibodies cross-reactive with hFSH exhibited high binding affinity (0.3ϫ10 9 -1.6ϫ10 9 M -1 ). The binding capacity was volunteers (nos. 9, 10 and 12) as early as day 30-50 and in two (nos. 1 and 5) between days 70 and 80 of immunization. maximal on days when antibody titre was high (between days 30 and 80) and reached minimal values by day 140, when the Whereas the titre of the antibody population cross-reactive with hFSH was markedly reduced by day 110, that reactive antibody titre was low ( Table III) . Considering that the mean FSH concentration in normal human males is between 3 and with oFSH reached low values only by day 140 and beyond. The reason why the volunteers did not respond to the booster 15 mIU/ml (1-5 ng/ml), the antibody titre between days 30 and 80 of immunization should be more than adequate to injections given on days 40 and 70 was sought by examining the resting antibody concentrations to oFSH at the time the neutralize endogenous FSH.
The bioneutralizing capacity of the antibody was determined boosters were given. The antibody titres to oFSH between days 50 and 70 were still very high (binding capacity 1140 Ϯ by pre-incubating 125 I-labelled hFSH with sera samples of volunteers prior to incubation with a particulate sheep testicular 110 ng oFSH/ml), and appeared more than adequate to neutralize the booster dose given. Based on total blood volume of receptor preparation (Table III) . Sera from individual volunteers a Based on the results (direct binding of the hormone ligand to the antibody) provided in Figure 1 . b Receptor binding inhibition was determined by pre-incubating 125 I-labelled hFSH (~200 000 cpm/tube) with 50 µl of volunteer serum overnight at 4°C prior to addition of the sheep testicular receptor preparation and continuing incubation for 60 min at room temperature. Polyethylene glycol (PEG 6000) was added to a final concentration of 5% to facilitate completion of precipitation. Use of 50 µl of normal human serum inhibited binding of 125 I-labelled hFSH to the receptor by only 10-15%. the human (~2.5 l), a booster dose of 100 µg oFSH may result in a circulating level of~40 ng/ml. Since we followed a fixed injection schedule and antibody titration was done boosters should not have been given on the days prescribed. We now believe that for the response to be good the boosters should be given only once in 100-120 days. Though only 26-45% of the 'free' circulating antibodies generated to oFSH cross-reacted with hFSH, all volunteers exhibited such reactivity and the binding affinity was uniformly high (0.65ϫ10 9 Ϯ 0.5ϫ10 9 M -1 ). The capacity of the antibody to bind endogenous FSH (hFSH) was high between days 30 and 80 of immunization and this concurs with the observation that no 'free FSH' was detectable between those days. Even in the earlier study in the monkey, no circulating 'free FSH' was detectable at time points when 'free' antibody was present (Aravindan et al., 1993) . In the receptor binding inhibition assay, used to determine bioneutralizing activity of the antibody, it was observed that a 50 µl aliquot of serum from an individual volunteer had maximal inhibitory activity in the range 73-95%, and this correlated with the high antibody titre existing at that time as determined by conventional binding procedures. of LH and TSH, as well as of testosterone, thyroxine and triiodothyronine, remained unaltered following immunization, tion of chromatin structure using flow cytometry. Two parameters were employed to determine this: (i) acridine it can be concluded that the antibody produced is specific to FSH and does not react with the other pituitary glycoprotein orange binding to DNA following acid denaturation and (ii) ethidium bromide binding to DNA following treatment with hormones.
Immunization of men with oFSH using the dose schedule dithiothreitol. The results clearly indicated that FSH deprivation had a marked effect on sperm chromatin compaction (Aravinreported here did not result in any adverse physiological effects, since haematology, serum biochemistry and hormonal dan et al., 1991) . Evenson and colleagues (Ballachey et al., 1988; Evenson, 1989) have demonstrated quantifiable differprofiles remained within normal ranges and were unaltered. No evidence for production of autoantibodies to non-specific ences in the quality of spermatozoa voided by proven fertile as compared to infertile human males as well as by control as tissues was obtained. This essentially corroborates the results of the earlier studies in monkeys (Srinath et al., 1983 ; Sehgal compared to chemically induced infertile bulls. We therefore used the chromatin structure assay procedure as described by et al., 1991), which indicated that, following immunization with FSH, occurrence of either immune complexes in the Evenson (1989) to determine whether FSH immunization affected the quality of spermatozoa voided by immunized circulation or the presence of precipitated immune complexes in a variety of tissues was not apparent using immunofluorescence human volunteers. The results showed a distinct pattern of change in decondensation of sperm chromatin structure, very techniques.
With a view to obtaining an assessment of the ability of the similar to that exhibited by monkeys immunized with oFSH as well as by a category of infertile men (as reported by antibody generated to block endogenous FSH action in vivo, sperm counts and quality and the seminal plasma transferrin Evenson, 1989) . Interestingly, the change in pattern was correlated with the antibody titres persisting at different periods concentration were determined. In the earlier monkey study it had been observed that sperm counts were significantly reduced of sperm sampling and analysis (H.Krishnamurthy, K.M. Prasanna Kumar and N.R.Moudgal, unpublished observation). only after 120 days of immunization, acute oligospermia and infertility arising by 200 days after immunization (Moudgal, Based on studies on transferrin concentrations in seminal fluid from normal and vasectomized men, it has been suggested 1981; Moudgal et al., 1992) . This suggests that the desired effect can been seen after continuous FSH deprivation for 3-that Ͼ80% of seminal transferrin comes from the testis (Orlando et al., 1985) . Sertoli cells cultured in the presence 4 sperm cycles. Considering that in the human one sperm cycle is~60-65 days, we believe that, in the present study, of FSH stimulation are known to produce transferrin (Skinner and Griswald, 1992) . Hence, the reduction in seminal transendogenous FSH was neutralized for too short a time (~50-80 days) for us to observe a significant reduction in sperm ferrin observed in the FSH-immunized volunteers achieves significance, as it can be used as a parameter to assess Sertoli production. The reduction in sperm counts that was observed in the immunized volunteers (33-64%) is therefore a first cell function in an FSH-deprived state. In support of this, the seminal plasma of long-term (Ͼ5 years) oFSH-immunized positive indication of what may occur (acute oligospermia) if deprivation of endogenous FSH support is maintained for a bonnet monkeys showed a 92% reduction (from 5.1 Ϯ 0.8 to 0.38 Ϯ 0.04 µg human transferrin equiv./ml; P Ͻ 0.01) in continuous period of Ͼ200 days.
Although Nieschlag (1985) also found that immunization transferrin concentration compared with controls. Seminal transferrin is therefore likely to provide a reliable index of of monkeys with oFSH led to severe impairment of spermatogenesis, he recommended abandoning this approach for contraseminiferous tubular function since concentrations of this protein have been found to be low in patients exhibiting oligoception as the animals exhibited resurgence in spermatogenesis to some extent following repeat boosting over a 4.5 year and azoospermia (Holmes et al., 1982; Orlando et al., 1985) . It can therefore be inferred that in man Sertoli cell dysfunction period and azoospermia was not achieved. However, no fertility testing was undertaken by this group. While the partial resurcan be achieved by immunization with oFSH. The current study is a forerunner of a detailed clinical gence in spermatogenesis observed could be due to repeat excessive boosting with oFSH in close succession, our studies trial and shows that administration of oFSH, a heterologous hormonal protein, in a relatively mild adjuvant (Alugel) elicits (Moudgal et al., 1992) as well as those of others (Raj et al., 1991; Srivatsava and Das, 1992) in monkeys have clearly a satisfactory immune response in adult human male volunteers. The antibodies generated are able to specifically bind to hFSH shown that oligospermia obtained as a consequence of FSH deprivation is compatible with establishment of infertility. A as well as bioneutralize the activity of endogenous FSH. The data also suggest that oFSH vaccine administered at the dose variety of parameters have been used to assess the quality of spermatozoa voided by monkeys immunized with oFSH.
used here is relatively safe for human usage. It should be possible to increase the hFSH antibody titre, as well as prolong Besides routine indices such as sperm numbers, viability, motility, gel penetrability and sperm acrosin and hyaluronidase its bioefficacy, by giving a booster once in 100 days, instead of once in 20-30 days as used currently, and perhaps using activity, which all showed significant reduction following immunization with oFSH for Ͼ6 months (Moudgal et al., recently discovered enhancers of adjuvant activity, such as sodium phthalyl derivative of lipopolysaccharide (SPLS) 1992; Moudgal and Aravindan, 1993) , the spermatozoa of immunized monkeys were also incapable of binding to either (Deshmukh and Talwar, 1995) or monophosphoryl lipid A (MPL) immunostimulant (Rudback et al., 1995) already cleared homologous monkey oocytes (Raj et al., 1991) or to zonadenuded hamster oocytes (Sharma and Das, 1992) . Spermatofor human use. Use of human instead of ovine FSH as an antigen in the human is feasible, but this would entail zoa from immunized monkeys were also analysed for compac-
